Not Yet Recruiting PHASE3 INTERVENTIONAL 2-arm NCT07387549

A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis (ELASCOPE)

A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis

Sponsor: Ipsen

Conditions Primary Sclerosing Cholangitis

Interventions Elafibranor Placebo

Updated 2 times since 2026 Last updated: Feb 27, 2026 Started: Apr 14, 2026 Primary completion: Apr 30, 2031 Completion: May 31, 2031

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Primary Sclerosing Cholangitis, this trial is actively recruiting participants. The trial is conducted by Ipsen and has accumulated 2 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

2 versions recorded

Mar 2026 — Present [monthly]

Not Yet Recruiting PHASE3
Feb 2026 — Mar 2026 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ipsen

Data source: Ipsen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.